No Data
Poinsettia: 2024 performance forecast
ApicHope Pharmaceutical (300723.SZ) announces a预亏, expecting a net loss of 0.472 billion yuan to 0.68 billion yuan for the fiscal year 2024, turning from profit to loss.
ApicHope Pharmaceutical (300723.SZ) released its performance forecast for 2024, predicting that the annual net profit attributable to shareholders will be...
Overview of the lifting of restrictions on the circulation of A-share stocks | January 17.
According to the Zhitong Finance APP, on January 17th, 12 listed companies had their restricted shares released, with a total market value of approximately 9.663 billion yuan. The specific details of the restricted share release today are as follows: Stock abbreviation Stock code Restricted share type Released share quantity Pangang Group Vanadium & Titanium Resources 000629 Stock-based Incentive 3.9867 million Harbin Electric Corporation Jiamusi Electric Machine 000922 Stock-based Incentive 2.34 million NARI Technology 600406 Stock-based Incentive 11.883 million Lanzhou Banks 001227 Pre-issue shares 2.85 billion Shenzhen Jieshun Science And Technology Industry 002609 Stock-based Incentive 0.1936 million Shanghai Yaoji Technology 0
ApicHope Pharmaceutical (300723.SZ): Wholly-owned subsidiary has obtained the registration certificate for Amlodipine Besilate Tablets.
On January 14, Gelonghui reported that ApicHope Pharmaceutical (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Amlodipine Besylate Tablets.
Is ApicHope Pharmaceutical (SZSE:300723) Using Too Much Debt?
ApicHope Pharmaceutical (300723.SZ): ApicHope Pharmaceutical's biological product, injectable Yanhuoning and Shenmai drink (Dangshen formula) is expected to be selected for centralized volume procurement.
On December 31, Glonhue announced that ApicHope Pharmaceutical (300723.SZ) disclosed that its wholly-owned subsidiary ApicHope Biomedical Co., Ltd. (abbreviated as "ApicHope Biomedical") participated in the national centralized procurement conducted by the National Chinese Patent Medicine Joint Procurement Office. According to the document "Announcement of the Proposed Selected Results of the National Chinese Patent Medicine Procurement Alliance Centralized Procurement" published by the National Chinese Patent Medicine Joint Procurement Office on December 30, 2024, on the Hubei medical insurance service platform, ApicHope Biomedical's products, Injected Yanhu Ning and Shen Mai Yin (Dangshen formula), are proposed to be selected in this centralized procurement.
Do ApicHope Pharmaceutical's (SZSE:300723) Earnings Warrant Your Attention?
